Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer Craig Reynolds, MD, David Barrera, DO, Robert Jotte, MD, PhD, Alexander I. Spira, MD, Charles Weissman, MD, Kristi A. Boehm, MS, Sharon Pritchard, RN, Lina Asmar, PhD Journal of Thoracic Oncology Volume 4, Issue 12, Pages 1537-1543 (December 2009) DOI: 10.1097/JTO.0b013e3181c0a2f4 Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Overall and progression-free survival. Journal of Thoracic Oncology 2009 4, 1537-1543DOI: (10.1097/JTO.0b013e3181c0a2f4) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 Time to progression. Journal of Thoracic Oncology 2009 4, 1537-1543DOI: (10.1097/JTO.0b013e3181c0a2f4) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 Quality of life. Journal of Thoracic Oncology 2009 4, 1537-1543DOI: (10.1097/JTO.0b013e3181c0a2f4) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions